3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Magnetic Resonance Spectroscopy
10
X-Rays
7
Specimen Handling
7
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Biopsy
6
ulixertinib
3
palbociclib
3
larotrectinib
3
erdafitinib
3
Temozolomide
3
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
ivosidenib
2
ensartinib
2
Vemurafenib
2
Thalidomide
2
Paclitaxel
2
Nivolumab
2
LY3023414
2
Gemcitabine
2
Erlotinib Hydrochloride
2
Cisplatin
2
Carboplatin
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
trastuzumab deruxtecan
×
Genitourinary
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled